Prof Adam Cohen speaks to ecancer in an online interview for the virtual ASH 2020 meeting about the initial clinical activity and safety of cevostamab, a FcRH5/CD3 T-Cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma.
He explains that FcRH5 is a new target in multiple myeloma, but that it is almost universally expressed in myeloma patients making it an attractive target for new therapies.
Prof Cohen concludes by talking about the potential impacts of the study, saying that these early findings show proof of principle although noting that it is too soon to say how it will fit into treatment options.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.